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Aging is one of the most powerful independent risk 
factors for the development of atherosclerotic cardio-
vascular disease (CVD), and more than half of all 
cardiovascular deaths occur in people aged 75 years or 
more [1].  
Among many other explanations, this could be driven 
by age-related changes in the immune system. Systemic 
inflammation contributes to atherogenesis and an in-
creased low-level inflammation during the aging 
process (‘inflammaging’) has been proposed as a culprit 
for many age-related diseases, including CVD. 
Monocyte-derived macrophages are the most abundant 
immune cells in atherosclerotic plaques, and are key to 
the formation, growth, and rupture of these lesions. Our 
group recently reported that circulating levels of 
interleukin-6, interleukin-1-receptor antagonist, and 
interleukin-18-binding protein increase with aging [2]. 
In addition, monocyte production capacity for several 
pro-atherogenic inflammatory cytokines was higher 
with increasing age.  
In the past few years, three novel mechanisms have 
been proposed to contribute to this age-related 
activation of the innate immune system. First, cellular 
senescence, a permanent arrest of cell growth, is asso-
ciated with an enhanced secretion of pro-inflammatory 
mediators, e.g. cytokines [3]. Secondly, due to an 
accumulation of acquired mutations in hematopoietic 
stem cells that confer a competitive advantage, >10% of 
subjects aged over 70 years have significant amounts of 
mutant clones in peripheral leukocytes, which is called 
clonal hematopoiesis of indeterminate potential (CHIP). 
CHIP is associated with an increased risk for CVD 
because these clonal leukocytes have an increased 
NLRP3 inflammasome-mediated interleukin-1β secre-
tion [4]. Thirdly, we and others have described that 
innate immune cells can effectively build a non-specific 
immunological memory that results in an increased 
proinflammatory phenotype, a process which is termed 
trained immunity.  
Recent studies have shown that circulating monocytes 
and myeloid progenitor cells in the bone marrow have 
the intriguing capacity to reprogram towards a long-
term non-specific pro-inflammatory phenotype follow-
ing initial exposure to microorganisms or microbial 
products [5]. Although beneficial in the context of 
resistance against reinfections, this mechanism might be 
detrimental in non-infectious chronic inflammatory con- 
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ditions in which myeloid cells contribute to disease 
progression, such as atherosclerosis. We have recently 
proposed this mechanism to contribute to the well-
known association between acute and chronic infections 
and atherosclerotic CVD [6]. Interestingly, trained 
immunity is not only induced by microbial products, but 
also by endogenous sterile atherogenic stimuli such as 
oxidized low-density lipoprotein (oxLDL) or lipo-
protein (a) [7].  
It is now key to elucidate the mechanisms that drive 
trained immunity, since this might reveal novel targets 
for preventive drug treatment. We have previously 
reported that reprogramming of intracellular metabolic 
pathways and epigenetic reprogramming are two fun-
damental processes in trained immunity, that are closely 
intertwined [7]. Briefly, trained monocytes and macro-
phages have avid glycolytic capacity and an increased 
glutaminolysis that feeds into the Krebs cycle. 
Intermediate metabolites from these pathways co-
regulate the activity of epigenetic enzymes, which 
culminates in long-term activation of pro-inflammatory 
gene transcription by enrichment of activating histone 
marks and increase chromatin accessibility. Important-
ly, these adaptations not only occur in circulating 
mature monocytes, but also in hematopoietic stem and 
progenitor cells in the bone marrow niche, which 
explains the observation that trained monocytes remain 
present in the circulation after initial stimulation for 
more than three months [8].  
In conclusion, in the past five years, immunological 
research has flourished in identifying novel mechanisms 
that modulate immune cell function. Because these 
mechanisms involve gradual accumulation of somatic 
mutations (CHIP) or the long-term adaptation to 
environmental cues (trained immunity), they are of 
particular interest for age-related disease such as CVD. 
Further elucidation of these pathophysiological pro-
cesses, in combination with innovative drug develop-
ment and drug-delivery systems that enable to target 
specific cells types, might provide completely novel 
classes of drugs to prevent atherosclerotic 
cardiovascular disease.      
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